Latest Breaking News On - Euronext oslo stock exchange - Page 3 : comparemela.com

Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update

Readout of topline result expected in March 2024 from UV1 randomized Phase II trial INITIUM in Ultimovacs’ lead indication, advanced malignant melanomaTopline result will report primary endpoint of.

Hans vassgJoachim midttunDrug administrationEuronext oslo stock exchangeFast trackCarlos de sousaHazard ratioOverall survivalOrphan drugNorwegian securities tradingFinancial manager

Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024

Study protocol enables readout of the INITIUM trial after all patients have been followed for a minimum of 18 months, or after 70 patients have progressed or died.As of today, the 70.

Vestre viken drammenBristol myers squibbOslo university hospitalEuronext oslo stock exchangeHalle universityCarlos de sousaFast trackOrphan drugVestre vikenDrammen hospitalHuman leukocyte antigen

Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint

Dose-escalation, first-in-human Phase I trial showed good safety and tolerability across all dose-cohorts, meeting the primary endpointData included observations of immune activation with.

Oslo university hospitalEuronext oslo stock exchangeTetanus epitope targetingCarlos de sousaChief executive officerOslo universityUltimovac tetanus epitope targetingAbuse regulationNorwegian securities trading

Ultimovacs Announces Resignation of Aitana Peire from Board of Directors

Ultimovacs Announces Resignation of Aitana Peire from Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Aitana peireJonas einarssonEuronext oslo stock exchangeCanica future of healthJohns hopkins universityJohns hopkinsInvestment directorUltimovac boardUltimovacs boardOrdinary annual meeting

Ultimovacs Announces Completion of Patient Enrollment in Supplementary Study to INITIUM, UV1 Phase II Trial in Malignant Melanoma

The supplementary study to INITIUM is designed to provide in-depth data on the biological activity and mode of action of the vaccine-induced T cells, to support the next stages of.

Bristol myers squibbHalle universityEuronext oslo stock exchangeOslo university hospitalChief medical officerHuman leukocyte antigen